Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 CMV Vaccine in Healthy Participants 9 to 25 Years of Age
NCT05575492Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2022
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of mRNA-1647 in cytomegalovirus infection (CMV), sponsored by Moderna Inc. Started Nov 2022; status: completed.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05575492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05575492.